Obesity is one of the most prevalent issues in modern society, primarily caused by reduced physical activity and unhealthy dietary habits (
1). Weight gain and fat accumulation in obesity are often accompanied by a loss of muscle mass, which alters body composition and further increases fat mass (
2). These changes raise the risk of developing obesity-related conditions such as cardiovascular disease, type 2 diabetes, and insulin resistance (
3). The reduction in muscle mass due to obesity can negatively affect metabolic and physiological systems (
4). Skeletal muscle secretes soluble factors known as myokines, which play a role in regulating metabolic pathways and physiological processes in other tissues (
5).
Myonectin, also referred to as C1Q/TNF-related protein 15 (CTRP15), is a well-known myokine that is sensitive to nutrient levels (
6). Studies have shown that myonectin not only regulates lipid metabolism but also plays a significant role in the erythropoietic stress response, particularly in iron mobilization within the liver (
7). Additionally, myonectin inhibits macrophage inflammation and cardiac apoptosis, contributing to the prevention of acute myocardial ischemic injury (
6,
7). Its secretion from skeletal muscles enhances free fatty acid consumption, metabolism, and overall quality of life, while reducing cardiovascular risk factors (
8).
Physical activity and nutrition influence myonectin expression, which promotes the uptake of plasma free fatty acids into adipose tissue through the expression of fatty acid transporters (FATP412, FATP) (
8). Myonectin regulates metabolic interactions between adipose and muscle tissues (
9), with levels decreasing during fasting and rising in response to glucose or lipid intake (
10). Furthermore, myonectin is involved in the phosphorylation of AMPK2, stimulation of fatty acid oxidation, glucose uptake via glucose transporters, and overall regulation of energy balance, glucose and fat metabolism, and insulin sensitivity (
6). Alterations in circulating myonectin levels can therefore affect a wide range of physiological processes. Myonectin is an essential regulator of the glucose metabolism (
11). Disturbances in myonectin secretion have been linked to the development of insulin resistance (
12). Regular physical activity plays a protective role against chronic metabolic diseases such as type 2 diabetes and insulin resistance (
13). Numerous studies have demonstrated that both high-intensity and moderate-intensity exercise stimulate the secretion of various factors from tissues across different body regions, with secretion levels varying according to exercise intensity (
6,
14). For instance, previous research has shown that high-intensity interval training (HIIT) exerts a greater influence on tissue signaling modulation compared to resistance training (
15). Myonectin levels tend to decrease in individuals with low levels of physical activity, whereas physical activity increases myonectin levels (
16). Another study found that myonectin stimulates glucose transporters in skeletal muscle and increases adenosine monophosphate kinase 3 activity, thereby enhancing glucose uptake (
17).
In contrast, voluntary wheel running for two weeks was shown to increase myonectin levels in serum and its expression in the gastrocnemius and soleus muscles of rats (
18). Additionally, new findings indicate that myonectin gene expression decreased after nine weeks of endurance training (
19). However, a separate study documented a rise in myonectin gene expression following a single session of exercise (
20). Myonectin levels have been reported to be lower in patients with type 2 diabetes and obesity (
21,
22), but physical activity has been shown to elevate both the expression and circulation of myonectin in skeletal muscle (
22). Despite these findings, limited research has compared the effects of HIIT and moderate-intensity continuous training (MICT) on myonectin-dependent responses.